Søndergaard I, Poulsen L K, Osterballe O, Weeke B
Medical Dept. TTA, Div. of Allergology and Laboratory for Medical Allergology, Rigshospitalet, University of Copenhagen, Denmark.
Allergy. 1991 Jan;46(1):10-9. doi: 10.1111/j.1398-9995.1991.tb00536.x.
Detailed evaluation of the IgE and IgG-subclass immune response during immunotherapy can now be performed by crossed radio immunoelectrophoresis (CRIE). Some new concepts are introduced facilitating the handling of the vast amount of data obtained by quantitating the immune response. These concepts are "distance" between antibody responses and "immune response width". The 20 patients included in this study were pollen-allergic patients who underwent specific immunotherapy in a 3-year prospective study. It was found that the immune response during immunotherapy was restricted to IgG1 and IgG4 antibodies. The semi-quantitative CRIE analysis correlated with the RAST analysis for the IgE samples before start of immunotherapy, for the IgG1 samples at week 12, and for all the IgG4 samples. During immunotherapy the number of IgG1 antibodies directed to the different antigens increased towards 11 antigens and decreased towards six. For the IgG4 antibodies the number of reactions increased towards 15 antigens and decreased towards four. The increase is generally paralleled by an increase in quantitative immune response as well. For some of the antigens a rise in the IgE antibodies is contrasted by a fall in the IgG4 antibody response, and for other antigens the opposite was true, indicating a regulatory mechanism between the IgE and the IgG4 synthesis. The IgE immune response to a number of antigens, including the major allergens before the start of immunotherapy, was quantitatively diminished during the period of immunotherapy when IgG1 was present early (week 12) in the period, and for other antigens there was a rise in IgE without an early IgG1 antibody response. This suggests that IgG1 can have a regulating influence on the IgE synthesis. Finally, we have found that IgE antibodies with specificities not present in the samples taken before immunotherapy were formed during immunotherapy. These new IgE antibodies do not, however, seem to impair the outcome of treatment.
现在可以通过交叉放射免疫电泳（CRIE）对免疫治疗期间的IgE和IgG亚类免疫反应进行详细评估。引入了一些新概念，便于处理通过定量免疫反应获得的大量数据。这些概念是抗体反应之间的“距离”和“免疫反应宽度”。本研究纳入的20例患者为花粉过敏患者，他们在一项为期3年的前瞻性研究中接受了特异性免疫治疗。结果发现，免疫治疗期间的免疫反应仅限于IgG1和IgG4抗体。半定量CRIE分析与免疫治疗开始前IgE样本、第12周IgG1样本以及所有IgG4样本的RAST分析相关。免疫治疗期间，针对不同抗原的IgG1抗体数量朝着11种抗原增加，朝着6种抗原减少。对于IgG4抗体，反应数量朝着15种抗原增加，朝着4种抗原减少。这种增加通常也伴随着定量免疫反应的增加。对于某些抗原，IgE抗体的升高与IgG4抗体反应的下降形成对比，而对于其他抗原则相反，这表明IgE和IgG4合成之间存在调节机制。在免疫治疗期间，当IgG1在早期（第12周）出现时，对多种抗原（包括免疫治疗开始前的主要过敏原）的IgE免疫反应在数量上减少，而对于其他抗原，IgE升高但没有早期IgG1抗体反应。这表明IgG1可以对IgE合成产生调节作用。最后，我们发现免疫治疗期间形成了免疫治疗前样本中不存在特异性的IgE抗体。然而，这些新的IgE抗体似乎并未影响治疗结果。
